Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial
Article in BMC Cancer (December 2022)
The most recent citing publications are shown below. View all 22 publications that cite this research output on Dimensions.
Article in BMC Cancer (December 2022)
Preprint in Research Square (June 2022)
Article in Cochrane Database of Systematic Reviews (May 2021)